Name | Value |
---|---|
Revenues | 42.0K |
Cost of Revenue | 44.0K |
Gross Profit | -2.0K |
Operating Expense | 8,182.0K |
Operating I/L | -8,184.0K |
Other Income/Expense | 974.0K |
Interest Income | 474.0K |
Pretax | -7,210.0K |
Income Tax Expense | 786.0K |
Net Income/Loss | -7,210.0K |
Sera Prognostics, Inc. is a women's health diagnostic company specializing in developing and commercializing biomarker tests to improve pregnancy outcomes. The company's flagship product, the PreTRM test, is a blood-based biomarker test designed to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. Additionally, Sera Prognostics is working on a range of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.